Clinical	0	8	O
significance	9	21	O
of	22	24	O
plasma	25	31	B-Gene_or_gene_product
endostatin	32	42	I-Gene_or_gene_product
in	43	45	O
acute	46	51	O
myeloid	52	59	O
leukemia	60	68	O
/	68	69	O
myelodysplastic	69	84	O
syndrome	85	93	O
.	93	94	O

BACKGROUND	96	106	O
:	106	107	O
Endostatin	108	118	B-Gene_or_gene_product
,	118	119	O
a	120	121	O
C	122	123	O
-	123	124	O
terminal	124	132	O
fragment	133	141	O
of	142	144	O
collagen	145	153	B-Gene_or_gene_product
XVIII	154	159	I-Gene_or_gene_product
,	159	160	O
is	161	163	O
an	164	166	O
endogenous	167	177	O
angiogenesis	178	190	O
inhibitor	191	200	O
.	200	201	O

While	202	207	O
endostatin	208	218	B-Gene_or_gene_product
is	219	221	O
being	222	227	O
investigated	228	240	O
for	241	244	O
its	245	248	O
usefulness	249	259	O
in	260	262	O
treating	263	271	O
solid	272	277	B-Pathological_formation
tumors	278	284	I-Pathological_formation
,	284	285	O
its	286	289	O
significance	290	302	O
in	303	305	O
hematologic	306	317	O
malignancies	318	330	O
is	331	333	O
unknown	334	341	O
.	341	342	O

METHODS	343	350	O
:	350	351	O
The	352	355	O
authors	356	363	O
evaluated	364	373	O
plasma	374	380	B-Gene_or_gene_product
endostatin	381	391	I-Gene_or_gene_product
(	392	393	O
PE	393	395	B-Gene_or_gene_product
)	395	396	O
levels	397	403	O
using	404	409	O
an	410	412	O
enzyme	413	419	O
linked	420	426	O
immunoassay	427	438	O
in	439	441	O
71	442	444	O
patients	445	453	B-Organism
with	454	458	O
acute	459	464	O
myeloid	465	472	O
leukemia	473	481	O
(	482	483	O
AML	483	486	O
)	486	487	O
and	488	491	O
43	492	494	O
patients	495	503	B-Organism
with	504	508	O
myelodysplastic	509	524	O
syndrome	525	533	O
(	534	535	O
MDS	535	538	O
)	538	539	O
,	539	540	O
and	541	544	O
correlated	545	555	O
PE	556	558	B-Gene_or_gene_product
with	559	563	O
various	564	571	O
clinical	572	580	O
parameters	581	591	O
.	591	592	O

RESULTS	593	600	O
:	600	601	O
There	602	607	O
was	608	611	O
no	612	614	O
significant	615	626	O
difference	627	637	O
in	638	640	O
the	641	644	O
median	645	651	O
PE	652	654	B-Gene_or_gene_product
level	655	660	O
between	661	668	O
AML	669	672	O
/	672	673	O
MDS	673	676	O
patients	677	685	B-Organism
and	686	689	O
the	690	693	O
normal	694	700	O
controls	701	709	O
.	709	710	O

Nevertheless	711	723	O
,	723	724	O
patients	725	733	B-Organism
who	734	737	O
achieved	738	746	O
complete	747	755	O
remission	756	765	O
(	766	767	O
CR	767	769	O
)	769	770	O
had	771	774	O
a	775	776	O
significantly	777	790	O
lower	791	796	O
median	797	803	O
PE	804	806	B-Gene_or_gene_product
level	807	812	O
compared	813	821	O
to	822	824	O
those	825	830	O
who	831	834	O
did	835	838	O
not	839	842	O
.	842	843	O

In	844	846	O
multivariate	847	859	O
analysis	860	868	O
,	868	869	O
PE	870	872	B-Gene_or_gene_product
was	873	876	O
found	877	882	O
to	883	885	O
be	886	888	O
a	889	890	O
significant	891	902	O
(	903	904	O
P	904	905	O
=	906	907	O
0	908	909	O
.	909	910	O
03	910	912	O
)	912	913	O
predictor	914	923	O
of	924	926	O
overall	927	934	O
survival	935	943	O
(	944	945	O
OS	945	947	O
)	947	948	O
with	949	953	O
adjustment	954	964	O
of	965	967	O
the	968	971	O
other	972	977	O
baseline	978	986	O
covariates	987	997	O
,	997	998	O
including	999	1008	O
patient	1009	1016	B-Organism
age	1017	1020	O
,	1020	1021	O
history	1022	1029	O
of	1030	1032	O
antecedent	1033	1043	O
hematologic	1044	1055	O
disorders	1056	1065	O
,	1065	1066	O
and	1067	1070	O
the	1071	1074	O
use	1075	1078	O
of	1079	1081	O
protective	1082	1092	O
environments	1093	1105	O
.	1105	1106	O

The	1107	1110	O
prognostic	1111	1121	O
value	1122	1127	O
of	1128	1130	O
PE	1131	1133	B-Gene_or_gene_product
was	1134	1137	O
also	1138	1142	O
evaluated	1143	1152	O
by	1153	1155	O
dividing	1156	1164	O
MDS	1165	1168	O
/	1168	1169	O
AML	1169	1172	O
patients	1173	1181	B-Organism
into	1182	1186	O
high	1187	1191	O
and	1192	1195	O
low	1196	1199	O
PE	1200	1202	B-Gene_or_gene_product
groups	1203	1209	O
using	1210	1215	O
the	1216	1219	O
median	1220	1226	O
PE	1227	1229	B-Gene_or_gene_product
level	1230	1235	O
of	1236	1238	O
normal	1239	1245	O
controls	1246	1254	O
as	1255	1257	O
the	1258	1261	O
cut	1262	1265	O
-	1265	1266	O
off	1266	1269	O
.	1269	1270	O

The	1271	1274	O
authors	1275	1282	O
found	1283	1288	O
that	1289	1293	O
patients	1294	1302	B-Organism
in	1303	1305	O
the	1306	1309	O
high	1310	1314	O
PE	1315	1317	B-Gene_or_gene_product
group	1318	1323	O
survived	1324	1332	O
for	1333	1336	O
a	1337	1338	O
significantly	1339	1352	O
shorter	1353	1360	O
time	1361	1365	O
than	1366	1370	O
those	1371	1376	O
patients	1377	1385	B-Organism
in	1386	1388	O
the	1389	1392	O
low	1393	1396	O
PE	1397	1399	B-Gene_or_gene_product
group	1400	1405	O
.	1405	1406	O

CONCLUSIONS	1407	1418	O
:	1418	1419	O
PE	1420	1422	B-Gene_or_gene_product
is	1423	1425	O
a	1426	1427	O
useful	1428	1434	O
prognostic	1435	1445	O
predictor	1446	1455	O
of	1456	1458	O
CR	1459	1461	O
and	1462	1465	O
OS	1466	1468	O
for	1469	1472	O
AML	1473	1476	O
/	1476	1477	O
MDS	1477	1480	O
patients	1481	1489	B-Organism
.	1489	1490	O

The	1491	1494	O
mechanism	1495	1504	O
underlying	1505	1515	O
the	1516	1519	O
association	1520	1531	O
between	1532	1539	O
high	1540	1544	O
PE	1545	1547	B-Gene_or_gene_product
and	1548	1551	O
poor	1552	1556	O
clinical	1557	1565	O
outcome	1566	1573	O
is	1574	1576	O
unclear	1577	1584	O
,	1584	1585	O
although	1586	1594	O
it	1595	1597	O
may	1598	1601	O
be	1602	1604	O
related	1605	1612	O
to	1613	1615	O
the	1616	1619	O
possible	1620	1628	O
PE	1629	1631	B-Gene_or_gene_product
reflection	1632	1642	O
of	1643	1645	O
tumor	1646	1651	B-Pathological_formation
burden	1652	1658	O
.	1658	1659	O

